Trial Profile
The glucokinase (GK) activator MK-0599 lowers plasma glucose concentrations in healthy non-diabetic subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2010
Price :
$35
*
At a glance
- Drugs MK 0599 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 05 Nov 2010 New trial record.